Entera Bio Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ENTX | GPCR | KLRA | LXRX | 0NZU.IL | SEPN | |
|---|---|---|---|---|---|---|
| Market cap | 540.90M | 1.45B | 1.66B | 658.53M | 14.45B | 2.23B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.7 | -9.6 | -3.0 | -7.8 | — | -24.7 |
| Price/book | 21.2 | 1.1 | 0.0 | 3.8 | 8.2 | 5.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +0.33% | −39.17% | −51.62% | +5.80% | −43.38% | +154.68% |
| Today | +1.97% | +0.05% | +1.75% | +1.37% | +1.66% | +9.57% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ENTX news ›Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of o... Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR…
Entera Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entera Bio (ENTX) with an Overweight rating. Entera is positioned for significant upside with EB613, a p... Entera Bio initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald initiated…
Entera Bio initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Entera Bio (ENTX) with an Outperform rating and $10 price target Published first on TheFly – the ultimat... Entera Bio initiated with an Outperform at LifeSci Capital LifeSci Capital initiated coverage…
Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Average Price Target of $9.60
Read Our Latest Stock Analysis on Entera Bio Entera Bio (NASDAQ:ENTX – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’…
Entera Bio appoints Laura Hamill director for Dec. 1
Entera Bio Ltd. appointed biopharmaceutical executive Laura Hamill as a Class I director, effective December 1, 2026; she will also join the audit and corporate governance and nomination committees on that date. Pursuant to Section 13 or…
Entera Bio initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Entera Bio (ENTX) with a Buy rating and $11 price target Published first on TheFly – the ultimate source for ... Entera Bio initiated with a Buy at Guggenheim Guggenheim initiated coverage of Entera Bio…
Guggenheim starts Entera with Buy on N-tab platform potential
Guggenheim last night initiated coverage of Entera Bio (ENTX) with a Buy rating and $11 price target The firm says its bullish view on Entera s... Guggenheim starts Entera with Buy on N-tab platform potential Guggenheim last night…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- defenseworld.net1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.